R115777

R115777 is a farnesyltransferase inhibitor that is primarily used in the field of oncology. It is also known by its trade name, Zarnestra, and its generic name, Tipifarnib.

Overview

R115777 works by inhibiting the enzyme farnesyltransferase, which is involved in the post-translational modification of proteins. This process is crucial for the function of several proteins, including the Ras protein, which is often mutated in cancer. By inhibiting farnesyltransferase, R115777 prevents the proper functioning of these proteins, thereby inhibiting the growth of cancer cells.

Clinical Trials

R115777 has been tested in several clinical trials for various types of cancer, including leukemia, non-small cell lung cancer, and breast cancer. While the results have been mixed, some studies have shown promise, particularly in patients with certain genetic mutations.

Side Effects

Like all chemotherapy drugs, R115777 can have side effects. These can include nausea, vomiting, diarrhea, and fatigue. More serious side effects can include neutropenia, a condition characterized by low levels of neutrophils, a type of white blood cell.

Future Research

While R115777 has not yet been approved for use in the United States, research is ongoing. Future studies will likely focus on identifying the specific patient populations that may benefit most from this treatment, as well as optimizing the dosing and administration of the drug.

See Also

• Farnesyltransferase inhibitor
• Chemotherapy
• Clinical trial

<img src="" alt="" />

This chemical compound or drug related article is a stub. You can help WikiMD by expanding it.